Filing Details
- Accession Number:
- 0001062993-23-023100
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-12-22 16:36:26
- Reporting Period:
- 2023-12-21
- Accepted Time:
- 2023-12-22 16:36:26
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1267565 | Collegium Pharmaceutical Inc | COLL | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1443841 | Joseph Ciaffoni | C/O Collegium Pharmaceutical, Inc. 100 Technology Center Drive Stoughton MA 02072 | President And Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2023-12-21 | 4,357 | $21.34 | 279,357 | No | 4 | M | Direct | |
Common Stock | Disposition | 2023-12-21 | 4,357 | $30.38 | 275,000 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Purchase) | Disposition | 2023-12-21 | 4,357 | $0.00 | 4,357 | $21.34 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
16,875 | 2030-02-05 | No | 4 | M | Direct |
Footnotes
- The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2023.
- The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.13 to $30.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- Twenty-five percent (25%) of the option vests and becomes exercisable on February 10, 2021, and the balance vests in equal quarterly installments (rounded up to the nearest whole share of common stock) over the following three-year period, subject to the Reporting Person's continued service with the Issuer.